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DOES SHORTER HEMODIALYSIS INCREASE
THE RISK OF DEATH?
Petar Kes1 and Dra¹ko PavloviÊ2
1Department of Nephrology and Dialysis, Sestre milosrdnice University Hospital, 2Department of Hemodialysis, Sveti
Duh General Hospital, Zagreb, Croatia
SUMMARY · Improvement in technology has made it possible to deliver a high dialysis dose in a
shorter period of time. Studies of the relationship between dialysis treatment duration and mortality
have revealed that the risk of death increased significantly as the treatment time was reduced. The
longer duration and increased frequency of dialysis achieve an excellent clearance of small- and middle-
weight toxins, enable equilibration of tissue and vascular compartments, improve appetite and per-
mit liberalization of diet, while gentle ultrafiltration allows for better control of hypertension. Better
clearance of uremic toxins, normalization of cellular and extracellular volume, and improved nutri-
tion result in a significant decrease in morbidity and mortality of dialyzed patients. With most of
dialyzers in use, adequate hemodialysis can be delivered in 4 to 5 hours, especially in a setting of
maximal blood and high dialysate flow, and low access recirculation. Although controversial, the
preliminary evidence available favor the use of a biocompatible membrane and more frequent or
prolonged dialysis to ensure adequate removal of small- and middle molecular weight toxins, yet
preventing the loss of essential solutes.
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Introduction
Since the landmark inception of hemodialysis (HD)
for the management of end-stage renal disease (ESRD)
in 19601, renal replacement therapy (RRT) has entered a
new technical era with the introduction of bicarbonate
buffer, biocompatible, high-flux membranes, and volu-
metric ultrafiltration control. Armed with technical ad-
vancements and reassured by the definition of adequacy
of dialysis by urea kinetics2,3, short HD had gradually
become the accepted practice in the 1980s4. Kramer et al.5
have described the wisdom of shortening the duration of
HD when they observed a significantly higher mortality
in ESRD patients dialyzed for less than 12 hours weekly.
Held et al.6 have confirmed that patients treated for less
than 3.5 hours three times weekly had a twice relative
mortality risk compared with patients receiving HD for
4 or more hours. On the other hand, the Centre de Rein
Artificial (Tassin, France) report on an unparallelled 69%
10-year survival rate, highest hematocrit values without
erythropoietin treatment, and lowest incidence of hyper-
tension without use of antihypertensive drugs, with the
old-time method of prolonged slow HD (PHD)7-9. How-
ever, the catabolic rate of dialysis and indiscriminate depu-
ration of solutes10-12 have raised concern and uncertainty
about the safety and consequences of PHD technique13.
Kt/V and Risk of Death
Central to the evaluation of the adequacy of short treat-
ment methods is the definition of adequacy, an issue that
is still incompletely solved. The National Cooperative Di-
alysis Study (NCDS)14-16 has established urea as a valid sur-
rogate marker for uremic toxins and ushered in the era of
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kinetic modeling, but has not defined the standard for op-
timal dialysis. The statement by Gotch and Sargent17 from
1985, that a Kt/V of 1.0 represents a dose of dialysis which
results in the minimal possible morbidity, and that increas-
ing HD further is “of no apparent clinical value”, has since
been challenged using data of the NCDS itself14-16. Both
re-examination of these data and of Gotch’s analysis17, and
clinical studies of the relationship of urea removal and
ESRD patient outcome18,19 indicate that the morbidity and
mortality rates are improved by dialysis of 1.2 or greater. In
a series of 2,311 maintenance HD patients in the USA,
Held et al.20 found the risk of death to decrease progres-
sively as Kt/V was increased to 1.3, but not beyond that rate.
Collins et al.21 also found that the greater the Kt/V, the
lower the risk of death. They report that, when a Kt/V
greater than 1.0 and lower than 1.2 was taken as a refer-
ence, the relative risk of death was 0.67 for Kt/V 1.2 · 1.4,
and 0.65  for Kt/V >1.4 in 1,082 non-diabetic ESRD pa-
tients. In 691 diabetic HD patients, the relative risk of death
was 0.70 for Kt/V 1.2 · 1.4, and 0.59 for Kt/V >1.421.
Charra et al.7 report on a remarkably good survival rate for
445 HD patients treated over the last 20 years. These pa-
tients were treated with HD for 24 hours weekly using Kiil
dialyzers, and an average Kt/V of 1.67 (survival was 87%
at 5 years, 75% at 10 years, 55% at 15 years, and 43% at 20
years)7. In 53,867 patients on three times weekly HD in
Japan, the Patient Registration Committee of the Japanese
Society for Dialysis Therapy ( JSDT)22 report on a progres-
sive decrease in the risk of death as Kt/V was increased to
1.8, however, no further decrease in the risk of death was
observed beyond that rate.
The difference in survival on HD among the USA,
Europe, Japan and Tassin (France) results may be related
to the difference in the dose of dialysis (Kt/V) or in du-
ration of HD sessions. The Tassin group7 and JSDP22
have recommended a minimal dose equivalent to a Kt/V
of 1.6 and 1.8, respectively, in order to provide a safety
limit. Such an approach, combined with a much more
effective blood pressure control and appropriate diet, may
be the future gold standard for HD therapy.
Dialysis Duration and Risk of Death
Owen et al.23, in a retrospective analysis of 13,473 HD
patients found no association of the risk of death with HD
session duration, but did find it with the plasma urea re-
duction rate (URR) of 65% to 70%, which showed an al-
most exponential correlation with a Kt/V of 1.3 to 1.6.
Other reports suggest that there is an association be-
tween the length of time on HD and risk of death7,24-26.
The technique, dialysis duration, and clinical outcome of
4 modalities of PHD are well documented in the literature.
The patients at the Centre de Rein Artificial currently re-
ceive HD with disposable flat-plate or hollow-fiber cellu-
losic, usually cuprophane, dialyzers with a surface area of
1.1 to 2.2 sqm7. Dialysate buffered with acetate (35 mmol/
L), generated by a central proportioning system, is deliv-
ered at 500 mL/min. Blood access is achieved through ar-
teriovenous fistula in a majority of patients (78%), or by
Thomas thigh shunts in some. Patients are dialyzed for 8
hours three times weekly, with a blood flow rate of 200 to
220 mL/min7. In Lecce (Italy), patients undergo HD ev-
ery other day for a minimum of 3 hours to reduce the pro-
longed 72-hour weekend interdialytic interval24. A high
level of depuration is targeted and achieved using individu-
alized blood (>300 mL/min) and dialysate (500 to 800 mL/
min) flow. Lecce HD has evolved with time and the initial
cuprophane membranes (1.2 to 1.6 sqm) have been replaced
by more biocompatible and larger (1.4 to 2.2 sqm) synthetic
membranes such as polysulfone, polymethylmethacrylate,
and AN69. Vascular access is through a distal arteriovenous
fistula in all patients24. During nocturnal HD practised in
Canada25, the patients dialyse themselves 6 to 7 times
weekly for 8 to 10 hours at night25. A modified monitor is
used to deliver bicarbonate-based dialysate (100 to 200 mL/
min) and blood (250 to 300 mL/min) at relatively low rates.
In contrast to the Tassin group, a biocompatible polysulfone
membrane (0.7 to 1.8 sqm) is used in nocturnal HD. In an
attempt to increase the clearance further, the Toronto group
has recently resorted to a larger surface area membrane, and
increased dialysate and blood flow rates. The vascular ac-
cess is mostly through Uldall-Cook internal jugular cath-
eters or arteriovenous fistula in some patients. The latest
part of the nocturnal HD project is that the patients are
monitored remotely from a central station through the
Internet25. In a different technique, Bouncristiani et al.26
tried to solve the conflicting need of best depuration with-
out intolerance by increasing the frequency of dialysis to a
daily pattern. The patients received ultra-short, low-effi-
ciency bicarbonate HD using a biocompatible polyacryloni-
trile membrane with a surface area of 1 sqm. Blood access
was achieved through arteriovenous fistula, using an aver-
age blood flow rate of 275 mL/min. Most patients dialyzed
themselves at home every day for a short duration of 90 to
120 min26.
Studies have suggested but did not demonstrate an
association of longer weekly HD with a lower risk of
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death. They have also failed to clarify whether the better
patient prognosis was due to longer HD sessions or to the
greater dialysis doses. The Kt/V values tend to be high in
patients treated with prolonged HD.
Dialysis Duration as an Independent Factor of
Death Risk
A potentially important aspect of an optimal HD
treatment is the duration of dialysis treatment. Dialysis
duration should be long enough to minimize the clinical
effects of rapid ultrafiltration, and to provide adequate
solute clearance to prevent uremia. Although the choice
of dialyzer size, blood flow rate, and dialysate flow rate
affects the solute clearance, the most influential prescrip-
tion parameter affecting the dose of dialysis is dialysis
duration. Today we acknowledge that increasing dialysis
duration has a beneficial effect on the patient’s outcome
mostly because of improved removal of small molecular
weight solutes. Outcome studies including NCDS14-16
have failed to support an independent risk of shortened
HD time. However, additional considerations that modu-
late the relationship between dialysis duration and solute
removal have recently surfaced.
There are a number of inherent limitations to HD that
result in the loss of effective clearance. These limitations
cause an inequality between the effective and prescribed
clearance, invalidating the assumption that changes in di-
alysis duration can be compensated solely by proportional
modifications in prescribed clearance. Some technical and
physiological limitations relate to the fact that blood flow
to the dialyse and to various capillary beds is arranged in
a set of parallel circuits, and that the body is not a single
compartment for urea removal27,28.These limitations have
important ramifications concerning the HD treatment
prescription and its adequacy. In addition, when consid-
ering the appropriate duration of dialysis, one must weight
those factors that degrade effective clearance so that the
compensating increases in the prescribed dialysis treat-
ment duration are adequate. Even when ESRD patients
take advantage of current technology, large, high-flux dia-
lyzers, and high blood and dialysate flow rates, a total body
Kt/V in excess of 1.0 to 1.2 will require a minimum treat-
ment duration of 4 hours in many HD patients29. Unfor-
tunately, without studying cardiac output, cardiopulmo-
nary recirculation, access flow, and access recirculation in
each individual patient, it will be impossible to know ex-
actly the time required to lengthen a specific patient’s HD
session. Only direct quantification of urea removal from
the dialysate30 may eliminate the need of a detailed evalu-
ation of each HD patient’s physiology, more accurately
define total body effective clearance, and provide a more
quantitative basis for the determination of optimal HD
treatment duration.
Urea clearance estimated by Kt/V has traditionally
been accepted as a yardstick for adequacy of dialysis31.The
mean Kt/V achieved per session by the Tassin group7 and
Toronto group25 was 1.67±0.41 and 1.0±0.23, respectively.
Considering that the Tassin patients were dialyzed 3 times
weekly7, and Toronto patients received 6 or 7 HD sessions
weekly, the weekly Kt/V should have been greater with
nocturnal HD practised in Toronto25. O’Sullivan et al.32
performed nocturnal HD in a small number of patients
with a large surface area (1.8 sqm) polysulfone dialyzer
and achieved an astonishing weekly Kt/V of 11.79 to
18.59. The Kt/V delivered weekly is in the range of 2.4
to 3.6 for daily short HD26 and 4.62±0.76 for Lecce
HD24. Although the change in urea concentration has
been assumed to bear a direct and regular relationship with
the concentration of other not clearly identified toxins, it
is probably not true. There is increasing evidence that
uremic syndrome is more than the accumulation of small,
water-soluble, non-protein bound compounds, suggest-
ing a pathogenic role for the denounced middle molecu-
lar weight uremic toxins33,34. Patients in Tassin received
23.8±2.2 sqm HD weekly (m2/h/wk)35 which, when es-
timated by the dialysis index of Babb et al.36, yielded
1.53±0.32.37. Similar data are not available for nocturnal
HD25 and daily short HD26, however, given the high-flux
membrane (polysulfone and polyacrylonitrile) used and
longer duration of dialysis (8 to 10 hours) in nocturnal
HD technique25, they should be capable of delivering
similar or even better clearance of middle weight mol-
ecules37.  Analysis of the Tassin data suggests that a re-
duction in morbidity and mortality rates may be achieved
by an increase in dialysis index35,36, but not by an increase
in Kt/V9, implying that clearance of small and middle
molecules may be vital for decreased morbidity and mor-
tality rates37-39.
In order to determine whether the duration of HD is
an independent factor in the risk of death, the JSDT 22,27
attempted to compute the impact of HD session duration
on the death risk, which was adjusted by Kt/V, using data
of 71,193 HD patients from the 1997 survey. Results of
the analysis indicated that even when the higher risk of
death, associated with shorter HD session duration, was
adjusted for Kt/V, a progressive decrease in the risk of
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death was seen as the session duration was prolonged until
it reached 5.5 hours27.The same analysis also showed that
even when the higher risk of death associated with lower
Kt/V was adjusted for HD session duration, a progressive
decrease in the higher mortality risk was seen as the Kt/
V increased until it reached 1.827.
Conclusion
It is not certain whether the effect of reduced dialysis
time implies reduction of an already inadequate dialysis
dose, or whether there is a mortality risk intrinsic to short
time itself, such as increased tendency to hypertension or
cardiovascular disease. However, it is certain that the trend
to shorter dialysis time has led to underdialysis and ad-
verse clinical effects. Prolonged HD features excellent
clearance of small- and middle molecular weight toxins,
better control of hypertension and anemia, and better re-
habilitation, attesting that it may be closer to the concept
of optimal dialysis. There is also a concern regarding the
risks of unsupervised home HD and uncertainty about
excessive depuration of essential solutes (nutrients, water-
soluble vitamins, trace elements), chronic stimulation of
the immune system (bioincompatible dialysis materials),
prolonged exposure to phthalate, endotoxins, and spalla-
tion products from plastic tubing, and increased net pro-
tein catabolism40-42.
Having sifted through available data on dialysis ad-
equacy and dose, and on the role of HD session length,
the following conclusions are made: 1) acceptable HD can
be delivered in 3 hours or less, but only to small patients
or those who have a significant residual renal function; 2)
with most of the dialyzers in use, adequate HD cannot be
delivered in 3 hours, especially in a setting of less than
maximal blood flow and/or high access recirculation; 3)
most conventional and even many high-flux and high-
efficiency dialyzers are incapable of adequately dialyzing
a middle-weight patient in less than 4 hours; and 4) the
available evidence favor the use of a biocompatible mem-
brane and more frequent but not very intense HD to en-
sure adequate removal of small- and middle weight tox-
ins, yet to prevent the loss of essential solutes.
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Saæetak
POVEÆAVA LI KRAÆA HEMODIJALIZA RIZIK OD SMRTI?
P. Kes i D. PavloviÊ
TehniËki napredak omoguÊio je da bolesnici dobiju veÊu dozu dijalize u kraÊem vremenu. Kada je ispitan odnos izmeðu
trajanja dijalize i smrtnosti, utvrðeno je da se rizik od smrti znaËajno poveÊao usporedno sa skraÊivanjem vremena provedenog
na dijalizi. Dulja dijaliza i veÊa uËestalost dijalize pozitivno utjeËu na uklanjanje malih i srednje velikih toksina, omoguÊavaju
ujednaËavanje razdiobe otopina izmeðu tkiva i krvnih æila, pobolj¹avaju apetit i dozvoljavaju slobodniju prehranu, a polagana
ultrafiltracija omoguÊava bolju kontrolu hipertenzije. Bolje odstranjivanje uremijskih toksina, normaliziranje staniËnog i
izvanstaniËnog volumena te bolja prehrana smanjuju stopu pobolijevanja i smrtnosti u dijaliziranih bolesnika. VeÊina danas
dostupnih dijalizatora omoguÊava, u uvjetima maksimalnog protoka krvi i visokog protoka dijalizata, a uz istodobno nizak
postotak recirkulacije u krvoæilnom pristupu, primjerenu hemodijalizu u trajanju od 4 do 5 sati. Iako neujednaËeni, rezultati
preliminarnih istraæivanja upuÊuju na to da uporaba biokompatibilnih membrana i Ëe¹Êa ili produæena dijaliza omoguÊavaju
primjereno uklanjanje toksina male i srednje velike molekularne veliËine, a da pritom ne dolazi do gubitka vaænih supstancija.
KljuËne rijeËi: hemodijaliza, trajanje dijalize, kratka dijaliza, produæena dijaliza, smrtnost
